"
Patient and Physician Preferences for Treating Adjuvant Melanoma: A Discrete Choice Experiment"
written by Kathleen Beusterien, Mark R. Middleton, Peter Feng Wang, Sumati Rao, Srividya Kotapati, Javier Sabater, Baiju Aurora, John F. P. Bridges,
published by
Journal of Cancer Therapy,
Vol.8 No.1, 2017
has been cited by the following article(s):
|
[1]
|
Rationale and recommendations for improving early-stage oncology diagnosis, treatment, and access
Journal of Medical Economics,
2026
DOI:10.1080/13696998.2026.2623775
|
|
|
|
|
[2]
|
Preferences of Dermato-oncologists for Adjuvant Therapy in Stage II Melanoma: A Nationwide Discrete Choice Experiment
Acta Dermato-Venereologica,
2025
DOI:10.2340/actadv.v105.44135
|
|
|
|
|
[3]
|
Patient preferences for stages II–IV melanoma treatments in the UK: results from a cross-sectional study
Melanoma Management,
2025
DOI:10.1080/20450885.2025.2570112
|
|
|
|
|
[4]
|
Preferences of melanoma patients to accept adjuvant therapy and toxicity – a qualitative substudy of the GerMelaTox-A project
Journal of Cancer Research and Clinical Oncology,
2024
DOI:10.1007/s00432-024-06014-8
|
|
|
|
|
[5]
|
Preferences for Adjuvant Immunotherapy in Adults with Resected Stage III Melanoma—A Discrete Choice Experiment
The Patient - Patient-Centered Outcomes Research,
2023
DOI:10.1007/s40271-023-00635-w
|
|
|
|
|
[6]
|
Patient Preferences in Targeted Pharmacotherapy for Cancers: A Systematic Review of Discrete Choice Experiments
PharmacoEconomics,
2022
DOI:10.1007/s40273-022-01198-8
|
|
|
|
|
[7]
|
Preferences for Immunotherapy in Melanoma: A Systematic Review
Annals of Surgical Oncology,
2020
DOI:10.1245/s10434-019-07963-y
|
|
|
|
|
[8]
|
A Guide to Measuring and Interpreting Attribute Importance
The Patient - Patient-Centered Outcomes Research,
2019
DOI:10.1007/s40271-019-00360-3
|
|
|
|
|
[9]
|
Approaches to decision-making among late-stage melanoma patients: a multifactorial investigation
Supportive Care in Cancer,
2018
DOI:10.1007/s00520-018-4395-7
|
|
|
|